It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Thank you.
Some features of ATS will be disabled while you continue to use an ad-blocker.
Marathon Pharmaceuticals has received FDA approval for an old drug used to treat Duchenne muscular dystrophy, deflazacort, and in the process has raised the price to ridiculously high levels.
You could previously import the generic medicine for about $1,200 per year, but it now costs a staggering $89,000 per year -- "just" $54,000 with discounts and rebates.
And since deflazacort (now rebranded as Emflaza) is classified as an orphan drug used to treat a rare disease, Marathon will both have a 7-year exclusive on US sales and a voucher to fast-track a future approval.
But now drug prices are on the health care industry’s radar, although a solution to the high cost is elusive.
Drugmakers say the fault lies with insurers that shift costs to consumers more for drugs than they do for hospital and medical care. Insurers say that’s because drugs are expensive and everyone feels the brunt of it. The truth is that both are right. The Affordable Care Act helped create this tension.
The law took big steps to extend drug coverage. Prescription drugs are one of 10 essential benefits that insurers are required to cover. It also closed the “donut hole,” or the coverage gap in Medicare Part D plans. It did so partly on the shoulders of drug companies, which are required to offer seniors a discount on their drugs. There is also a tax on drug manufacturers and importers.
But other than that, drug companies are largely unregulated. They can set their own prices. There are no restrictions on profit margins. And there is very little transparency into the pricing process.
By contrast, Obamacare is full of new rules governing insurance and is a radical departure from the way the market used to operate. It requires insurers to cover a wider array of benefits while it prohibits them from denying coverage based on preexisting conditions. It institutes new rules regarding how insurers set premiums. It limits insurers’ revenues and creates new standards of premium rate reviews. It also creates significant rules about plans’ benefit design, limiting cost-sharing, and setting up a system of tiers based on the share of costs covered by a particular plan.
These changes upended the health insurance market, and insurers’ have been forced to adapt. The catch is that insurers reflect the costs of health care in general, even more so now that there are caps on how much of a plan’s revenue can be used for marketing, administration and profits.
originally posted by: Phage
a reply to: Skywatcher2011
Yep. Then they go away. And then what?
originally posted by: Skywatcher2011
originally posted by: Phage
a reply to: Skywatcher2011
Yep. Then they go away. And then what?
Let the generics and free market competition come in.
And you wonder why Obama Care insurance premiums are set to skyrocket? Trump will need to land a smack down on these companies, and fast!
originally posted by: Phage
a reply to: Skywatcher2011
I agree about pharmaceutical corporations but you said this:
And you wonder why Obama Care insurance premiums are set to skyrocket? Trump will need to land a smack down on these companies, and fast!
How do you think Trump can "smack down" on these companies? The only thing he's mentioned is negotiating medicare payments.
I have no clue how the system or procedures work
originally posted by: Phage
a reply to: Skywatcher2011
I have no clue how the system or procedures work
From what I've seen so far, neither does he.